

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Ustekinumab for treating moderately to severely active Crohn’s disease after prior therapy

Batch 47

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Inadequate response to medical treatment can lead to surgery, which can have a significant impact on fertility, primarily for women, so this should be considered in terms of potential gender discrimination. This impact is exacerbated given the peak diagnosis period in the teens and twenties and surgery also carries particular issues for those following certain religious practices.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This is not an equality issue as there are current treatment options for people with Crohn’s disease and response to medical treatment is uncertain for any of the treatments offered for it.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the draft scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders have been identified.

Approved by Associate Director (name):Janet Robertson.....

Date: 28 September 2016